Envista Holdings Corp

NYSE:NVST

Medical - Equipment & Services

Healthcare
$23.75 +3.06%

+$0.76 today

Market cap
$3.81B
Beta
0.89
P/E (TTM)
62.0
EPS (TTM)
$0.41
52W Low $18.32High $30.42

Volume 1.92M

Average 2.94M

NVST Sales of Investments

Cash received from selling or redeeming investments.

Envista Holdings CorpNYSE: NVST

Sales of Investments · Q3 FY2026 · quarter ended Oct 2026

Sales of investments dips below year-ago levels

Q3 FY2026 sales of investments of $8.6M fell 4.4% year over year, behind the +6.7% change in trailing-twelve-month sales of investments. Sequentially, it rose 473.3% from the prior quarter. Over 3 fiscal years it compounded at -42.9% a year.

Context

  • Sales of investments amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
  • Sales of investments increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -4.4% toward the trailing-twelve-month pace of +6.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterOct 2026
$8.6M+473.3% QoQ
Last fiscal yearDec 2025
$10.4M+7.2% YoY
LTMOct 2026
$11.1M+6.7% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%——
1 year+7.2%——
3-year CAGR-42.9%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
10.4M USD
Year-over-year change
+7.2%
4-year CAGR
-2.3%

Sales of Investments vs competitors

How NVST compares with its peers on the latest reported figures

  • NVST's LTM Oct 2026 sales of investments of $11.1M is the 7th largest of the 11 companies compared; the peer median is $72.72M.
  • Its year-over-year change of +6.7% is the 3rd highest of 8, against a peer median of -17.7%.
  • Sales of investments amounts to 0.4% of revenue for NVST, versus a peer median of 0.9%.
NVST Competitors Peer median
Sales of Investments for NVST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$1.36B +148.4%+59.6%163.8%
APGEApogee Therapeutics, Inc.LTM Jun 2026$544.88M +24.1%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$395.01M -5.6%-6.6%59.0%
DYNDyne Therapeutics, Inc.LTM Jun 2026$157.88M -17.7%-6.6%—
GRALGRAIL, Inc.LTM Jun 2026$73.3M -87.5%—44.4%
ALHCAlignment Healthcare, Inc.LTM Mar 2026$72.15M -34.5%+215.7%1.7%
NVSTEnvista Holdings CorpLTM Oct 2026$11.1M +6.7%-42.9%0.4%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$1M -50.0%—0.0%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$0 ——0.0%
ICUIICU Medical, Inc.LTM Jun 2026$0 ——0.0%
PRVAPrivia Health Group, Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding NVST) $72.72M-17.7%+26.5%0.9%

Competitors are the stored peer set for NVST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income340.5M243.1M(100.2M)(1.12B)47M
Depreciation & Amortization151.9M162.1M162.6M123.1M116M
Deferred Income Tax00(37M)(29M)11.4M
Stock-Based Compensation28.2M30.5M30.7M35.3M37.6M
Change in Working Capital(203.2M)(271.7M)(108.4M)97.4M8.9M
Accounts Receivables(43.2M)(71M)(17M)10M(48.5M)
Inventory(66M)(39.9M)35.1M3.6M(29.1M)
Accounts Payables(20.3M)44.5M(46.3M)(1.2M)7.5M
Other Working Capital(73.7M)(205.3M)(80.2M)85M79M
Other Non-Cash Items44.2M18.7M328M1.23B54.8M
Operating Cash Flow361.6M182.7M275.7M336.5M275.7M
Capital Expenditures(54.7M)(75.7M)(58.2M)(33.8M)(45.3M)
Acquisitions (Net)310.4M(622.3M)000
Purchases of Investments000(32.8M)(9.9M)
Sales of Investments11.4M56M10.7M9.7M10.4M
Other Investing Activities(4.4M)(15.3M)(14.9M)2.3M(6.3M)
Investing Cash Flow262.7M(657.3M)(62.4M)(54.6M)(51.1M)
Debt Repayment(475.7M)(200K)115.4M(100M)(900K)
Common Stock Issued19.5M21.8M11.3M2.4M2.8M
Common Stock Repurchased0000(166.6M)
Dividends Paid00000
Other Financing Activities(9.4M)(9.1M)(7.8M)(6.1M)(6.2M)
Financing Cash Flow(465.6M)12.5M118.9M(103.7M)(170.9M)
Effect of Forex Changes26M(4.6M)900K(49.1M)88.9M
Net Change in Cash184.7M(466.7M)333.1M129.1M142.6M
Free Cash Flow306.9M107M217.5M302.7M230.4M

Envista Holdings Corp

NYSE:NVST

Intrinsic Alpha fair value

Locked

Current Price

$23.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.